Submit Manuscript  

Article Details

β-Sheet Breakers for Alzheimers Disease Therapy

[ Vol. 5 , Issue. 6 ]


Bieler S. and Soto C.   Pages 553 - 558 ( 6 )


A growing wealth of evidence indicates that the key pathological event in Alzheimers disease is the conversion of the normal soluble amyloid-β peptide into β-sheet-rich oligomeric structures which have a neurotoxic activity and ability to form insoluble amyloid deposits that accumulate in the brain. b-sheet breakers constitute a new class of drugs that are designed to specifically bind amyloid-β peptide and block and / or reverse this abnormal conformational change. In this article we review this approach, describe diverse compounds reported to have this activity and summarize the data supporting the view that b-sheet breakers could be serious candidates to combat this devastating disease.


alzheimer disease, amyloid, therapy


Protein Misfolding Disorders Laboratory, Department of Neurology, University of Texas Medical Branch,Galveston, TX, USA

Read Full-Text article